475|2389|Public
25|$|Ligocyte {{announced}} in 2007 {{that it was}} working on a vaccine and had started phase 1 trials. The company has since been taken over by Takeda. , a monovalent nasal vaccine had completed phase I/II trials, while bivalent intramuscular and nasal vaccines were at earlier stages of development. The two vaccines rely on using a <b>virus-like</b> <b>particle</b> that is made of the norovirus capsid proteins in order to mimic the external structure of the virus. Since there is no RNA in this particle, it is incapable of reproducing and cannot cause an infection.|$|E
2500|$|Stanley B. Prusiner of the University of California, San Francisco (UCSF) {{was awarded}} the Nobel Prize in {{physiology}} or medicine in 1997 [...] "for his discovery of Prions—a new biological principle of infection". However, Yale University neuropathologist Laura Manuelidis has challenged the prion protein (PrP) explanation for the disease. In January 2007, {{she and her colleagues}} reported that they had found a <b>virus-like</b> <b>particle</b> in naturally and experimentally infected animals. [...] "The high infectivity of comparable, isolated virus-like particles that show no intrinsic PrP by antibody labeling, combined with their loss of infectivity when nucleic acid–protein complexes are disrupted, make it likely that these 25-nm particles are the causal TSE virions".|$|E
2500|$|Protein subunit– {{rather than}} {{introducing}} an inactivated or attenuated micro-organism to an immune system (which {{would constitute a}} [...] "whole-agent" [...] vaccine), a fragment of it can create an immune response. Examples include the subunit vaccine against Hepatitis B virus that is composed of only the surface proteins of the virus (previously extracted from the blood serum of chronically infected patients, but now produced by recombination of the viral genes into yeast), the <b>virus-like</b> <b>particle</b> (VLP) vaccine against human papillomavirus (HPV) that is composed of the viral major capsid protein, and the hemagglutinin and neuraminidase subunits of the influenza virus. Subunit vaccine is being used for plague immunization.|$|E
40|$|<b>Virus-like</b> <b>particles</b> were {{purified}} from {{a single}} nonaflatoxin-producing isolate of Aspergillus flavus. The <b>virus-like</b> <b>particles</b> were spherical, measuring 27 to 30 nm in diameter, were electrophoretically homogeneous, and sedimented at approximately 49 S. The particles had a buoyant density of 1. 28 g/cm 3 in CsCl and contained no detectable nucleic acid...|$|R
40|$|AbstractAlphaviruses are {{comprised}} of a nucleocapsid core {{surrounded by a}} lipid membrane containing glycoprotein spikes. Previous work demonstrated that in vitro assembled core-like particles are similar in structure to the nucleocapsid core in the native virus. Here we demonstrate that in vitro assembled core-like particles can be inserted into viral glycoprotein-expressing cells to generate enveloped <b>virus-like</b> <b>particles.</b> These <b>virus-like</b> <b>particles</b> bud from cells like native virus, are similar in size to the native virus, and can enter cells to release {{the contents of the}} core-like particle into the cytoplasm of the cell. <b>Virus-like</b> <b>particles</b> can be used to infect cells with biological and non-biological cargoes. The generation of enveloped <b>virus-like</b> <b>particles</b> containing an in vitro core and in vivo synthesized glycoproteins has applications for gene and drug delivery, medical imaging, and also basic mechanistic studies of virus assembly...|$|R
40|$|VP 1 is {{the major}} viral coat protein of murine polyomavirus {{and can be used}} for the {{generation}} of <b>virus-like</b> <b>particles</b> in vitro. Here, we demonstrate that capsid assembly is an equilibrium reaction followed by oxidation of intracapsomere disulfide bonds, which are not essential for the formation of <b>virus-like</b> <b>particles</b> but enable complete particle assembly and prevent capsid dissembly...|$|R
50|$|Frazer {{convinced}} Zhou to {{join him}} at the University of Queensland, Brisbane, and in 1990 they began to use molecular biology to synthesize particles in vitro that could mimic the virus. In March 1991 Zhou's wife and fellow researcher, Xiao-Yi Sun, assembled by Zhou's instructions two proteins into a <b>virus-like</b> <b>particle</b> (VLP), resembling the HPV shell, from which HPV vaccine would ultimately be made.|$|E
5000|$|The crystal {{structure}} of a betanodavirus- T=3 Grouper nervous necrosis virus (GNNV)-like particle has been determined by X-ray crystallography. The <b>virus-like</b> <b>particle</b> contains 180 subunits of the capsid protein, and each capsid protein (CP) shows three major domains: (i) the N-terminal arm, an inter-subunit extension at the inner surface; (ii) the shell domain (S-domain), a jelly-roll structure; and (iii) the protrusion domain (P-domain) formed by three-fold trimeric protrusions.|$|E
5000|$|Like other parvoviruses, bocaparvoviruses have an icosohedral {{and round}} {{structure}} with T=1 symmetry. The capsid is non-enveloped, and composed of 60 copies {{of up to}} six types of capsid proteins (called VP1 through to VP6) which share a common C-terminal region. The structure of a <b>virus-like</b> <b>particle</b> composed only of VP2 protein was determined by cryo electron microscopy and image reconstruction. The diameter is around 21-22 nm. Genomes are linear, around 5.5kb in length ...|$|E
5000|$|... {{production}} of proteins, antibodies and <b>virus-like</b> <b>particles</b> for basic research and pharmaceutical development ...|$|R
40|$|Human astrovirus is an {{important}} cause of acute gastroenteritis. We have generated, for the first time, a vaccinia virus recombinant expressing the astrovirus 87 -kDa structural polyprotein. The results demonstrate that this expression results {{in the formation of}} <b>virus-like</b> <b>particles</b> in the absence of other astrovirus proteins and genomic RNA. The purified trypsin-activated <b>virus-like</b> <b>particles</b> strongly resemble the complete astrovirus particles...|$|R
40|$|Tissues from mink {{infected}} with aleutian disease virus were {{examined by the}} electron microscope {{for the presence of}} virus <b>particles.</b> <b>Virus-like</b> <b>particles,</b> measuring 22 nm in diameter, were observed in macrophages of spleen, mesenteric lymph node and in Kupffer cells in liver of mink ten to 13 days after infection. The <b>virus-like</b> <b>particles</b> were usually present in vacuoles inside the cytoplasm of macrophages and Kupffer cells and, occasionally, similar particles were observed inside the nucleus. Cells from uninfected mink did not contain such patricles. To correlate the existence of these <b>virus-like</b> <b>particles</b> with the presence of aleutian disease virus antigen in infected cells, tissues were processed for immunoferritin technique. It was found that aleutian disease virus antigen was present in vacuoles inside the cytoplasm of cells from the infected spleen, lymph node and liver, and that the location was {{similar to that of the}} 22 nm <b>virus-like</b> <b>particles.</b> In addition, some viral antigen was also detected as cytoplasmic granular material. The nuclei of some cells also contained aleutian disease virus antigen. The pattern of aleutian disease virus antigen was similar to the distribution of <b>virus-like</b> <b>particles</b> in cells of infected tissue. It is suggested that virus replication occurs inside the nucleus with subsequent accumulation of virus in the vacuoles of the cytoplasm...|$|R
50|$|<b>Virus-like</b> <b>particle</b> {{vaccines}} {{consist of}} viral protein(s) {{derived from the}} structural proteins of a virus. These proteins can self-assemble into particles that resemble the virus from which they were derived but lack viral nucleic acid, meaning {{that they are not}} infectious. Because of their highly repetitive, multivalent structure, virus-like particles are typically more immunogenic than subunit vaccines (described below). The human papillomavirus and Hepatitis B virus vaccines are two virus-like particle-based vaccines currently in clinical use.|$|E
50|$|A {{vaccine that}} targets PCSK9 has been {{developed}} to treat high LDL-particle concentrations. The vaccine uses a VLP (<b>virus-like</b> <b>particle)</b> as an immunogenic carrier of an antigenic PCSK9 peptide. VLP's are viruses that have had their DNA removed so that they retain their external structure for antigen display but are unable to replicate; they can induce an immune response without causing infection. Mice and macaques vaccinated with bacteriophage VLPs displaying PCSK9-derived peptides developed high-titer IgG antibodies that bound to circulating PCSK9. Vaccination was associated with significant reductions in total cholesterol, free cholesterol, phospholipids, and triglycerides.|$|E
50|$|Ligocyte {{announced}} in 2007 {{that it was}} working on a vaccine and had started phase 1 trials. The company has since been taken over by Takeda. , a monovalent nasal vaccine had completed phase I/II trials, while bivalent intramuscular and nasal vaccines were at earlier stages of development. The two vaccines rely on using a <b>virus-like</b> <b>particle</b> that is made of the norovirus capsid proteins in order to mimic the external structure of the virus. Since there is no RNA in this particle, it is incapable of reproducing and cannot cause an infection.|$|E
40|$|Fecal {{specimens}} {{were obtained}} from 1, 160 infants and young children with acute nonbacterial gastroenteritis {{over a period of}} 2 years. A total of 100 specimens {{were obtained from}} age-matched asymptomatic controls. The specimens were examined for the presence of viruses by electron microscopy. Viruses or <b>virus-like</b> <b>particles</b> frequently associated with enteritis were detected in 27 % (314 of 1, 160) of the symptomatic patients. No viruses or <b>virus-like</b> <b>particles</b> were detected in the 100 control subjects. Rotavirus was detected in 73 % (230 of 314) of the virus-positive samples. The mean age of rotavirus-positive patients was 11. 5 months, although the patients ranged in age from 2 weeks to 5 years. Of the symptomatic patients, 45 (14 %) exhibited small <b>virus-like</b> <b>particles</b> (15 to 40 nm) in the feces {{in the absence of any}} other detectable pathogen. Some of the <b>virus-like</b> <b>particles</b> observed in these patients appeared to be similar to astrovirus, and some appeared to be similar to the Otofuke agent or possibly minireovirus. Significantly, however, the mean age of infants with enteritis from whom these small <b>virus-like</b> <b>particles</b> were recovered was 4. 5 months (range, 10 days to 19 months). Our findings confirmed the already-known fact that rotaviruses constitute the most important cause of viral enteritis in young children. In addition, small viruses may be an important cause of gastroenteritis in infants under 5 months of age...|$|R
40|$|Immunotherapy of type-I-allergies is {{regarded}} as the most efficient treatment option besides allergen avoidance. Different forms of allergen preparations are used as well as different routes of application. <b>Virus-like</b> <b>particles</b> represent a potent vaccine platform with proven immunogenicity and clinical efficacy. The addition of toll-like receptor ligands and/or depot-forming adjuvants further enhances immune cell activation. This article will focus on the function of <b>virus-like</b> <b>particles</b> loaded with DNA rich in CpG-motifs and discuss clinical experience in treatment of allergic rhinitis. Evidence will be presented that clinically effective treatment can be obtained {{even in the absence of}} allergens. Results encourage further investigation of <b>virus-like</b> <b>particles</b> and CpG-motifs in immunotherapy, either as a stand alone product, or as adjuvants for allergen-specific immunotherapy...|$|R
40|$|Ultracentrifugation, {{particularly}} {{the use of}} sucrose or cesium chloride density gradients, is a highly reliable and efficient technique for the purification of <b>virus-like</b> <b>particles</b> and protein cages. Since <b>virus-like</b> <b>particles</b> and protein cages have a unique size compared to cellular macromolecules and organelles, the rate of migration {{can be used as}} a tool for purification. Here we describe a detailed protocol for the purification of recently discovered virus-like assemblies called bacterial encapsulins from Thermotoga maritima and Brevibacterium linens...|$|R
50|$|The {{virus has}} since been {{classified}} into the genus Orthohepevirus, and has been reassigned into the Hepeviridae family. The virus itself is a small non-enveloped particle.The genome is approximately 7200 bases in length, is a polyadenylated single-strand RNA molecule that contains three discontinuous and partially overlapping open reading frames (ORFs) along with 5' and 3' cis-acting elements, which have important roles in HEV replication and transcription. ORF1 encodes a methyltransferase, protease, helicase and replicase; ORF2 encodes the capsid protein and ORF3 encodes a protein of undefined function. A three-dimensional, atomic-resolution structure of the capsid protein {{in the context of}} a <b>virus-like</b> <b>particle</b> has been described.|$|E
5000|$|Stanley B. Prusiner of the University of California, San Francisco (UCSF) {{was awarded}} the Nobel Prize in {{physiology}} or medicine in 1997 [...] "for his discovery of Prions—a new biological principle of infection". However, Yale University neuropathologist Laura Manuelidis has challenged the prion protein (PrP) explanation for the disease. In January 2007, {{she and her colleagues}} reported that they had found a <b>virus-like</b> <b>particle</b> in naturally and experimentally infected animals. [...] "The high infectivity of comparable, isolated virus-like particles that show no intrinsic PrP by antibody labeling, combined with their loss of infectivity when nucleic acid-protein complexes are disrupted, make it likely that these 25-nm particles are the causal TSE virions".|$|E
5000|$|Protein subunit - {{rather than}} {{introducing}} an inactivated or attenuated micro-organism to an immune system (which {{would constitute a}} [...] "whole-agent" [...] vaccine), a fragment of it can create an immune response. Examples include the subunit vaccine against Hepatitis B virus that is composed of only the surface proteins of the virus (previously extracted from the blood serum of chronically infected patients, but now produced by recombination of the viral genes into yeast), the <b>virus-like</b> <b>particle</b> (VLP) vaccine against human papillomavirus (HPV) that is composed of the viral major capsid protein, and the hemagglutinin and neuraminidase subunits of the influenza virus. Subunit vaccine is being used for plague immunization.|$|E
5000|$|Leptopilina is a genus of {{parasitoid}} wasp in {{the family}} Figitidae. The genus {{is best known for}} the three Drosophila parasitoids Leptopilina boulardi, Leptopilina heterotoma and Leptopilina clavipes, used to study host-parasite immune interactions. The venom released by L. heterotoma during oviposition contains <b>virus-like</b> <b>particles</b> that delay host larval development and suppress the host cellular immune response. There is no evidence that these <b>virus-like</b> <b>particles</b> are the products of viral DNA as described in other parasitoid taxa, [...]|$|R
40|$|Infection with high-risk human papillomaviruses (HPVs) is an {{essential}} step in the multistep process leading to cervical cancer. There are approximately 120 different types of HPV identified: of these, 18 are high-risk types associated with cervical cancer, with HPV- 16 being the dominant type {{in most parts of}} the world. The major capsid protein of papillomavirus, produced in a number of expression systems, self assembles to form <b>virus-like</b> <b>particles.</b> <b>Virus-like</b> <b>particles</b> are the basis of the first generation of HPV vaccines presently being tested in clinical trials. <b>Virus-like</b> <b>particles</b> are highly immunogenic and afford protection from infection both in animal models and in Phase IIb clinical trials. A number of Phase III trials are in progress to determine if the vaccine will protect against cervical disease and, in some cases, genital warts. However, it is predicted that these vaccines will be too expensive for the developing world, where they are desperately needed. Another problem is that they will be type specific. Novel approaches to the production of <b>virus-like</b> <b>particles</b> in plants, second-generation vaccine approaches including viral and bacterial vaccine vectors and DNA vaccines, as well as different routes of immunization, are also reviewed. © 2005 Future Drugs Ltd...|$|R
40|$|In two laboratory-scale {{enclosures}} {{of water}} from the shallow, eutrophic Lake Loosdrecht (the Netherlands), the predominating filamentous cyanobacteria grew vigorously for 2 weeks, but then their populations simultaneously collapsed, whereas coccoid cyanobacteria and algae persisted. The collapse coincided with a short peak in the counts of <b>virus-like</b> <b>particles.</b> Transmission electron microscopy showed the morphotype Myoviridae phages, with isometric heads of about 90 nm outer diameter and > 100 -nm long tails, that occurred free, attached to and emerging from cyanobacterial cells. Also observed were other <b>virus-like</b> <b>particles</b> of various morphology. Similar mass mortality of the filamentous cyanobacteria occurred in later experiments, but not in Lake Loosdrecht. As applies to lakes in general, this lake exhibits high abundance of <b>virus-like</b> <b>particles.</b> The share and dynamics of infectious cyanophages remain to be established, and it is as yet unknown which factors primarily stabilize the host–cyanophage relationship. Observations on shallow, eutrophic lakes elsewhere indicate that the cyanophage control may also fail in natural water bodies exhibiting predominance of filamentous cyanobacteria. Rapid supply of nutrients appeared to be a common history of mass mortality of cyanobacteria and algae in laboratory and outdoor enclosures as well as in highly eutrophic lakes. [KEYWORDS: cyanobacteria, cyanophages, shallow lakes, <b>virus-like</b> <b>particles...</b>|$|R
50|$|On a 1989 sabbatical he met {{virologist}} Jian Zhou, {{and the two}} {{considered the}} problem of developing a vaccine for HPV - a virus that cannot be cultured without living tissue. Frazer convinced Zhou to join him, and in 1990 they began to use molecular biology to synthesize particles in vitro that could mimic the virus. In March 1991 Zhou's wife and fellow researcher, Xiao-Yi Sun, assembled by Zhou's instructions two proteins into a <b>virus-like</b> <b>particle</b> (VLP), resembling the HPV shell, from which HPV vaccine would ultimately be made. (The vaccine completely protects unexposed women against four HPV strains responsible for 70% of cervical cancers, which kill about 250,000 women annually.) Frazer and Zhou filed a provisional patent in June 1991 and began work on developing the vaccine within UQ. To finance clinical trials, Australian medical company CSL, and later Merck, were sold partial patents. (CSL has the exclusive license to sell Gardasil in New Zealand and Australia, Merck the license elsewhere.) GlaxoSmithKline independently used the same VLP-approach to develop Cervarix, under a later US patent, licensing Frazer's intellectual property in 2005.|$|E
40|$|In 1972, a 27 -nm <b>virus-like</b> <b>particle</b> was {{discovered}} by use of immune electron microscopy (IEM) in an infectious stool ®ltrate derived from an outbreak of gastroenteritis in an ele-mentary school in Norwalk, Ohio. IEM enabled the direct visualization of antigen-antibody interaction, as the particles were aggregated and coated by speci®c antibodies. This allowed the recognition and identi®cation of a 27 -nm <b>virus-like</b> <b>particle</b> {{that did not have}} a distinctive morphology, was low-titered, and was among the smallest viruses known. Serum antibody responses to the 27 -nm particle were demonstrated in key individuals infected under natural or experimental conditions; this and other evidence suggested that this <b>virus-like</b> <b>particle</b> was the etiologic agent of the Norwalk gastroenteritis outbreak. The fastidious 27 -nm Norwalk virus is now considered to be the prototype strain of a group of noncultivatable viruses that are important etiologic agents of epidemic gastroenteritis in adults and older children. I was invited to present my re¯ections on the discovery of the Norwalk virus. This is a personal odyssey that chronicles the steps in making the arduous leap from the discovery of a 27 -nm <b>virus-like</b> <b>particle</b> to its etiologic association with epi...|$|E
40|$|Adenovirus dodecahedron is a <b>virus-like</b> <b>particle</b> {{composed}} {{of only two}} viral proteins of human adenovirus serotype 3 {{that are responsible for}} virus attachment and internalization. We show here that this dodecameric particle, devoid of genetic information, efficiently penetrates human cells and can deliver large multimeric proteins such as immunoglobulins...|$|E
40|$|Dengue virus {{replication}} in mosquito cell cultures was observed by electron microscopy in one fatal and 40 classical isolates from a dengue type 2 outbreak in Rio de Janeiro and {{compared with the}} prototype New Guinea C strain. All the Brazilian isolates presented, beside the classical structured dengue virus <b>particles,</b> fuzzy coated <b>virus-like</b> <b>particles,</b> never observed in thereferencial New Guinea C virus strain. more numerous DEN- 2 virus <b>particles,</b> fuzzy coated <b>virus-like</b> <b>particles,</b> defective virus particles and smooth membrane structures inside the rough endoplasmic reticulum characterized the unique fatal isolate examined...|$|R
40|$|ELP-CP, a {{structural}} fusion protein of the thermally responsive elastin-like polypeptide (ELP) and a viral capsid protein (CP), was designed, and its assembly properties were investigated. Interestingly, this protein-based block copolymer could be self-assembled via two mechanisms into two different, well-defined nanocapsules: (1) pH-induced assembly yielded 28 nm <b>virus-like</b> <b>particles,</b> and (2) ELP-induced assembly yielded 18 nm <b>virus-like</b> <b>particles.</b> The latter were {{a result of}} the emergent properties of the fusion protein. This work shows the feasibility of creating a self-assembly system with new properties by combining two structural protein elements...|$|R
40|$|In a {{previous}} report (Huang SN: Hepatitis-associated antigen hepatitis: an electron microscopic study. Am J Pathol 64 : 483 - 500, 1971) liver biopsies of renal transplant patients who developed chronic progressive viral hepatitis associated with persistence of Australia antigenemia [Au(1) ] while under immunosuppressive therapy were studied. Predominantly intranuclear 210 - 250 A spherical, <b>virus-like</b> <b>particles</b> were revealed in 12 of 13 biopsies examined by electron microscope. No such particles {{were found in}} biopsies from Australia antigen negative patients. To investigate the relationship of these <b>virus-like</b> <b>particles</b> to Australia antigen, 2 of the Au(1) hepatitis renal transplant patients were restudied 6 to 8 months later. Liver biopsy material was prepared for light microscopy, immunofluorescent microscopy, electron microscopy and immunoelectron microscopy. The specificity of the anti-Au(1) serum {{used in this study}} was ascertained by immunodiffusion and immunoelectrophoresis, and by immunoelectron microscopic studies of the antigen-antibody complex prepared in vitro by mixing the ferritin-conjugated anti-Au(1) reagent with the purified Au(1) particles. Electron microscopy of biopsies from liver not treated with antibody showed that <b>virus-like</b> <b>particles</b> persisted in liver cells. Immunofluorescent microscopy of teased liver biopsy suspensions showed nuclear and some cytoplasmic fluorescence, indicating the cellular localization of Au(1). The immunoelectron microscopic preparations showed agglutination of the <b>virus-like</b> <b>particles</b> and the presence of antibody coupled ferritin in the intranuclear and cytoplasmic <b>particle</b> agglutinates. No <b>virus-like</b> <b>particles</b> were seen in the biopsy from a control patient without Au(1) antigenemia, and results of the immunoelectron microscopic procedure were negative. Our observations that massive amounts of Au(1) -associated particles are located in liver cell nuclei of individuals with chronic active hepatitis strengthen the hypothesis of Blumberg et al that Au(1) is an infectious agent and/or the antigenic determinant of a hepatitis virus...|$|R
40|$|MS 2 噬菌体病毒样颗粒广泛用于构建rnA病毒检测中的阳性对照品. 本文基于已构建的表达载体P CPHA,优化了表达载体在bl 21 (dE 3) 细胞中的表达条件. 结果表明在lb培养基中,菌液Od 600 = 0. 9 时,加入IPTg诱导 6 H,外壳蛋白的表达量达到最大,电镜下观察到表达出的产物呈现MS 2 噬菌体病毒颗粒结构,该病毒样颗粒在常温下至少可以保存 60 d, 64 ℃温度时 30 MIn内结构保持稳定. <b>Virus-like</b> <b>particle</b> of MS 2 {{bacteriophage}} {{was widely}} {{used as a}} kind of positive control in detection of RNA virus. Several expressional conditions of p CPHA vector that pack hemagglutinin(HA) gene segment of avian influenza virus were optimized inside E. coli BL 21 (DE 3) cell. The results showed coat protein expression level reaches the maximum at the broth OD 600 of 0. 9,IPTG induction 6 h and LB liquid medium. Expression product morphological structure was the same as MS 2 bacteriophage virus particles under scanning electron microscope. The structure of <b>virus-like</b> <b>particle</b> was stable at normal temperature for at least 60 d and 64 ℃ for at least 30 min...|$|E
40|$|Adenovirus dodecahedron (Dd), a nanoparticulate {{proteinaceous}} biodegradable <b>virus-like</b> <b>particle</b> (VLP), {{was used}} as a vector for delivery of an oncogene inhibitor to hepatocellular carcinoma (HCC) rat orthotopic model. Initiation factor eIF 4 E is an oncogene with elevated expression in human cancers. Cell-impermeant eIF 4 E inhibitor, cap structure analog (cap) and anti-cancer antibiotic doxorubicin (Dox) were delivered as Dd conjugates. Dd-cap and Dd-dox inhibited cancer cell culture proliferation up to 50 and 84 %, respectively, while with free Dox similar results could be obtained only at a 5 times higher concentration. In animal HCC model the combination treatment of Dd-cap/Dd-dox caused 40 % inhibition of tumor growth. Importantly, the level of two pro-oncogenes, eIF 4 E and c-myc, was significantly diminished in tumor sections of treated rats. Attachment to Dd, a <b>virus-like</b> <b>particle,</b> permitted the first demonstration of cap analog intracellular delivery and resulted in improved doxorubicin delivery leading to statistically significant inhibition of HCC tumor growth...|$|E
40|$|International audienceBombyx mori {{densovirus}} 1 (BmDNV- 1), a major pathogen of silkworms, causes significant {{losses to}} the silk industry. The {{structure of the}} recombinant BmDNV- 1 <b>virus-like</b> <b>particle</b> has been determined at 3. 1 -Å resolution using X-ray crystallography. It is the first near-atomic-resolution structure of a <b>virus-like</b> <b>particle</b> within the genus Iteravirus. The particles consist of 60 copies of the 55 -kDa VP 3 coat protein. The capsid protein has a β-barrel "jelly roll" fold similar to that found in many diverse icosahedral viruses, including archaeal, bacterial, plant, and animal viruses, {{as well as other}} parvoviruses. Most of the surface loops have little structural resemblance to other known parvovirus capsid proteins. In contrast to vertebrate parvoviruses, the N-terminal β-strand of BmDNV- 1 VP 3 is positioned relative to the neighboring 2 -fold related subunit in a "domain-swapped" conformation, similar to findings for other invertebrate parvoviruses, suggesting domain swapping is an evolutionarily conserved structural feature of the Densovirinae...|$|E
5000|$|Expression of {{the matrix}} protein VP40 is {{sufficient}} to generate <b>virus-like</b> <b>particles</b> (no viral genetic material) in a mammalian host that are remarkably indistinguishable from live virus, from a morphological standpoint ...|$|R
5000|$|... #Caption: Electron {{microphotograph}} (x50,000) of MCV capsids artificially {{produced as}} <b>virus-like</b> <b>particles</b> by expressing MCV structural proteins in cells. The 55-60 nm viral capsids have typical icosahedral symmetry found in polyomaviruses.|$|R
5000|$|Prions, {{named for}} their {{description}} as [...] "proteinaceous and infectious particles", lack any detectable (as of 2002) nucleic acids or <b>virus-like</b> <b>particles.</b> They resist inactivation procedures that normally affect nucleic acids.|$|R
